Administration of blood components - avoiding unnecessary costs by Bird, Arthur et al.
SAMJ FORUM
Since there are several blood component filters currently
available on the market, some of which are relatively
expensive, this article serves to place in perspective the
indications for their use.  
Blood components must be transfused through a sterile,
pyrogen-free transfusion set which has an in-line filter (170 µm
pore size), drip chambers and tubing.1,2 The filter serves to
remove potentially harmful clots and debris that may have
formed during collection or storage. Although the Transfusion
Services carefully inspect individual units before issuing, there
is a slight chance that a small clot could go undetected and
hence this filter is recommended for the administration of all
components. The cost of the set is approximately R30.  It
should be emphasised that the chances of clot formation
during storage are very low since red cells are mainly prepared
as buffy coat-poor concentrates mixed with an additive
solution and anticoagulant and contain very little plasma and
are relatively depleted of white cells and platelets.  Most
manufacturers recommend that the set be changed after 24
hours or following a specified number of units.  Trapped
protein and debris provide a potential medium for bacterial
growth; also, as filtered particles accumulate, the flow rate
decreases.  Platelets are given using a set containing a 170 µm
filter although the surface area of the filter is smaller than that
used for red cells.  Fresh-frozen plasma and cryoprecipitate are
also best given through this standard administration set in case
small fibrin strands are present.
Second-generation microaggregate filters (MAFs) containing
filters of 40 µm made an appearance in the 1970s and were
developed to remove very small aggregates of degenerating
platelets, leucocytes and fibrin that may form during storage
and pass through the standard filters. They are intended only
for red cell component filtration. Early studies appeared to
show a clinical benefit in respect of pulmonary function
(prevention of pulmonary microemboli) but other studies did
not confirm this benefit.3 Their use in cardiopulmonary bypass
surgery may be prudent to reduce postoperative morbidity
from arteriolar emboli, and specialised intra-arterial line MAFs
are available for these procedures.4 Their role in reducing
febrile non-haemolytic transfusion reactions (FNHTRs) has
been supplanted by the more efficient leucocyte removal filters
and the routine preparation of standard red cell concentrates
with removal of the buffy coat which is rich in white cells and
platelets. The MAFs cost approximately R160 and therefore add
appreciably to the cost of a red cell concentrate and can be used
only once.  We do not recommend the routine use of these
filters which we believe are being marketed as the filter of
choice, particularly in the private sector.
During the last decade sophisticated leucocyte depletion
filters have been developed which are able to remove 99.9%
(log 3), or more, leucocytes.  A more detailed discussion on
these filters appeared in the October 2001 SAMJ5 — suffice to
say they are considerably more expensive (over R300).  A
number of developed countries have elected to filter all red cell
and platelet components routinely before storage, despite the
lack of unequivocal evidence to support its universal
application.  The costs are considerable ($400 million in the
USAper annum) and therefore its universal introduction in
South Africa needs to be considered carefully in view of the
many competing health priorities. The transfusion services in
South Africa have reviewed the subject carefully and believe
there are selected indications for leucocyte-depleted blood
components — these are outlined in the article referred to.5
Nevertheless they probably bear repeating:
• If FNHTRs occur repeatedly or patients are on chronic
transfusion regimens.
• Platelets prepared from single donors by apheresis should be
by a technique that incorporates leucocyte depletion (all
modern cell separators have this capacity).
• Patients considered at risk for transfusion-transmitted
cytomegalovirus.
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• Patients who are potential haemopoietic transplant recipients
should receive leucocyte-depleted components from
inception of transfusion support.
• Intrauterine transfusions and all transfusions to infants
under 1 year of age.
It should also be noted that there is little clinical evidence to
support the routine use of leucocyte depletion filters for
plasma.
Filtration should be carried out within 48 hours of collection,
i.e. by the transfusion service. Bedside filters are not
recommended since consistent quality control is not possible
and older units will accumulate cytokines, etc. which may be
responsible for some of the side-effects attributed to white cells.
Obviously if individual clinicians believe that their patients
would benefit from leucocyte-depleted components for
indications other than those above, they should naturally
request this and the Services will issue accordingly.  By
monitoring the usage and gearing up accordingly the Services
will be in a position to meet any such demands.
We trust that this clarifies the role of filters in the
administration of blood components.
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‘He who pays the piper calls the tune’ is a remark from the old
German children’s story The Pied Piper of Hamlin . Historically
we can say that the tune has been ‘the medical aid will pay’.
Unfortunately, rising health care costs in the face of  finite
social resources have changed the tune to ‘the medical scheme
might not pay’. This tune might also signal the more important
role of health cost management within the medical industry.
Until recently it was easy to view industry and medicine as
separate entities. Medicine was a profession and industry a
business. Medicine had patients and industry had customers.
Today many consider medicine to be a business, the medical
industry, with business rules applying. This has brought about
sweeping changes. The number and intensity of clinical
interventions is growing faster than ever before, and the
expectations of a computer-literate society with its growing
concern for enhanced personal lifestyle are pressurising the
primary aims of medicine. In a lecture presented at the Royal
College of Physicians and Surgeons of Canada in Montreal
during September 1999 the past president of the American
Academy of Orthopedic Surgeons said the following: ‘The
medical profession is forced to consider medicine as the
medical industry and areas such as medical education,
research, hospitals, subspecialties, rehabilitation and investor-
owned managed care have become branches of the medical-
industrial complex.
‘Medicine has compromised professionalism to reap financial
benefits. Physicians long considered that advertising and
marketing themselves were inappropriate and demeaning.
Today, many physicians freely use all available media to
market themselves without shame or sanction. We have sold
our birthright for a pot of porridge.’1
Whether or not we as clinicians have sold our birthright to
treat and cure patients is open to debate, but we need to accept
and understand that the medical industry is indeed a new
concept in many ways. This is an industry that talks about
cost-effective health care, number needed to treat (NNT) as a
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